Use of liquid biopsy in monitoring therapeutic resistance in EGFR oncogene addicted NSCLC.

Liquid biopsy has emerged as a minimally invasive alternative to tumor tissue analysis for the management of lung cancer patients, especially for epidermal growth factor receptor ( EGFR ) oncogene addicted tumor. In these patients, despite the clear benefits of tyrosine kinase inhibitors therapy, the development of acquired resistance and progressive disease is inevitable in most cases and liquid biopsy is important for molecular characterization at resistance and, being non-invasive, may be useful for disease monitoring. In this review, the authors will focus on the applications of liquid biopsy in EGFR -mutated non small cells lung cancer at diagnosis, during treatment and at progression, describing available data and possible future scenarios.